Search
SWG Educational Activities
Recruitment trialsRecruitment is underway for the following trials:
Trial on precision hematology: Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies (EXALT-2); ClinicalTrials.
Chairs and Members
Chair (2022–2025 term)Philipp Staber, Medical University Vienna (Austria)
Co-chair (2022–2025 term)Caroline Heckman, FIMM, Helsinki (Finland)
SWG Steering Committee members (2022–2025 term)
Jean-Pierre Bourquin, Universitäts-Kinderspital Zürich (Switzerland)
Kirsten Grønbæk, University of Copenhagen (Denmark)
Eva Hellström Lindberg, Karolinska Institutet, Stockholm (Sweden)
Ulrich Jäger, Medical University Vienna (Austria)
Luca Malcovati,…
Publications
Robust scoring of selective drug responses method in Nature ProtocolsSWG members have published a method in Nature Protocols that allows robust scoring of selective drug responses for patient-tailored therapy selection.
Read morePublications
For the subgroup Rare hereditary blood cancers:
GATA2 monoallelic expression underlies reduced penetrance in inherited GATA2-mutated MDS/AML.
Highlights from the SWG
The following activities, which were organized by EMN, also constitute contributions to and participation in the work of the EHA SWG on Multiple Myeloma.
Read moreChairs and Members
ChairPieter Sonneveld (Rotterdam, The Netherlands)
Members
Niels Abildgaard (Odense, Denmark)
Meral Beksac (Ankara, Turkey)
Luca Berthamini (Rotterdam, Netherlands)
Lenka Bešše, Brno (Czech Republic)
Dr Bila (Belgrade, Serbia)
Nicole Brolli (Milano, Italy)
Sara Bringhen (Turin, Italy)
Mario Boccadoro (Turin, Italy)
Anna Maria Brioli (Bologna, Italy)
Annemiek Broyl (Rotterdam, Netherlands)—also Chair of Young…
SWG Educational Activities
In 2021, the SWG on Multiple Myeloma contributed a major part of the ESMO-EHA guidelines for multiple myeloma. The rapid changes of the treatment landscape for this disease require an adaptation of the guidelines.
Read morePublications
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
P. Sonneveld, A. Chanan-Khan, K. Weisel, A. K. Nooka, T. Masszi, M. Beksac, I. Spicka, V. Hungria, M. Munder, M.
- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- »